Pfizer completes Metsera acquisition, adding experimental GLP-1 and amylin candidates

Pfizer completed its acquisition of Metsera, the clinical-stage obesity and cardiometabolic drug developer, on Thursday, Nov. 13, 2025, ending a bidding contest with rival Novo Nordisk ^[1][2].

Pfizer paid $65.60 per share in cash, which it said represents an enterprise value of about $7.0 billion, plus a contingent value right of up to $20.65 per share in potential additional payments tied to three specified clinical and regulatory milestones ^[1]. Pfizer did not say what those milestones are ^[2]. Fierce Biotech reported the total deal value at around $10 billion, up from the roughly $7.3 billion value of the buyout agreement the two companies signed in September ^[2].

Metsera is now a wholly owned Pfizer subsidiary, and its shares stopped trading on the Nasdaq Global Select Market after the close of trading Thursday ^[1]. Pfizer said the transaction is expected to dilute its earnings through 2030, mainly to fund further investment in late-stage pipeline candidates, with updated numbers to come with its 2026 guidance later this year ^[1].

"This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine," Pfizer chairman and CEO Albert Bourla said in the release. "By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it" ^[1].

What Pfizer bought

Metsera's lead candidate is MET-097i, a GLP-1 receptor agonist given as a weekly or monthly injection that Pfizer says is about to begin Phase 3 development ^[1]. Also in the deal: MET-233i, a monthly amylin analog being tested in Phase 1 both alone and in combination with MET-097i; an oral GLP-1 receptor agonist in Phase 1; and additional preclinical nutrient-stimulated hormone therapeutics ^[1].

The purchase followed an unusual public fight. Pfizer and Metsera first agreed to a deal in late September, then Novo Nordisk made a surprise $6.5 billion upfront offer, outbidding Pfizer's earlier $4.9 billion upfront bid ^[2]. Pfizer went to court to try to block Novo's offer, calling it an attempt by a dominant company to suppress competition; a Delaware judge declined to stop Novo's bid, and the Federal Trade Commission warned Novo that the structure of its proposed buyout may not comply with U.S. merger law ^[2]. Metsera agreed to Pfizer's increased offer late on Nov. 7 ^[2]. Novo Nordisk already sells the obesity drug Wegovy (semaglutide) ^[2].

Why it matters for patients

None of the medicines Pfizer acquired is approved, so no one can get them now outside a clinical trial. MET-097i has not yet entered Phase 3, and Phase 3 testing is typically the longest and largest stage of development before a company can seek regulatory approval ^[1]. Pfizer's own disclosure lists risks that include unfavorable new clinical data and the possibility that regulators will not approve its pipeline products ^[1]. That means how well these drugs work, what side effects they cause, and when or whether they reach the market have not been reported.

For people already taking an approved GLP-1 medicine, the transaction does not change availability, coverage, prescribing or supply of any product on the market today. It does add a third large company to a field where Novo Nordisk is already established with Wegovy ^[2]. Pfizer describes its new candidates as "highly differentiated" and says they have the potential to reshape the treatment landscape, but that is the company's characterization, not a finding from completed trials ^[1].

The dosing schedules in development — a monthly injection option and an oral GLP-1 candidate ^[1] — are the kind of differences patients often ask about, but whether they translate into meaningful advantages is not yet known.

What happens next

Pfizer said its updated financial impact from the deal will be provided with its 2026 guidance, expected later this year ^[1]. MET-097i is described as about to begin Phase 3, with no start date disclosed ^[1]. The specific clinical and regulatory goals that would trigger the contingent value right payments have not been disclosed ^[2]. How many patients would eventually be enrolled in any of these trials, and when results might be available, has not been reported.